
Our Services
Supporting you every step of the way.

Explore our services by industry
BIOLOGICS
Quality Services
BIOLOGICS
Regulatory Services
Quality Management System (QMS) Compliance
-
cGMP Compliance for Biologics (21 CFR Parts 600-680, ICH Q10)
-
FDA & EMA GMP Readiness Audits for Biologics Manufacturing
-
Biologic-Specific QMS Implementation & Maintenance
-
Data Integrity & Compliance (FDA, EMA, ALCOA+ Principles)
-
ICH Q7 Compliance for API & Biologic Drug Substance Manufacturing
Good Manufacturing Practices (GMP) for Biologics
-
Facility Design & Environmental Monitoring Compliance (ISO 14644, EU GMP Annex 1)
-
GMP Audits for Biologics Manufacturers & Contract Development and Manufacturing Organizations (CDMOs)
-
Vendor & Supplier Qualification for Raw Materials & Excipients
-
Cold Chain Logistics & Storage Compliance
Process & Product Quality Control for Biologics
-
Analytical Method Development & Validation (ICH Q2, USP 1225, Ph. Eur.)
-
Bioprocess Validation & Scale-Up Compliance (ICH Q8, Q11, Q12)
-
Sterilization & Aseptic Processing Compliance
-
Viral Clearance & Contamination Control Strategies
-
In-Process Controls & Batch Release Testing for Biologics
Deviation Management, CAPA, & Root Cause Analysis
-
Deviation Investigations & GMP Non Conformance Handling
-
Corrective & Preventive Actions (CAPA) Implementation
-
Root Cause Analysis (RCA) for Manufacturing & Quality Issues
-
Change Control Management for Biologics Manufacturing
Quality Remediation & Compliance Support
-
FDA 483 & Warning Letter Remediation for Biologic Manufacturers
-
Regulatory Compliance Gap Assessments for Biologics
-
Post-Approval Quality & Compliance Support
-
Recall & Market Withdrawal Support
Biologics Labeling & Packaging Compliance
-
FDA & Global Labeling Compliance (21 CFR 610, 801, 211)
-
Serialization & Track-and-Trace (DSCSA, EU FMD, UDI Compliance for Combination Products)
-
Packaging Integrity & Stability Compliance (ICH Q1A, Q5C)
Post-Market Quality & Safety Compliance for Biologics
-
Biologic Product Complaint Handling & Investigations
-
Risk-Based Quality Audits & Post-Market Surveillance Compliance
-
Adverse Event & Pharmacovigilance Compliance (ICH E2E, FDA, EMA, WHO GVP)
-
Biologic Product Lifecycle Quality Management
Regulatory Strategy & Market Access
-
Biologic Product Regulatory Strategy Development (FDA, EMA, PMDA, NMPA, etc.)
-
Regulatory Pathway Determination (BLA, IND, Fast Track, RMAT, Breakthrough Therapy, Orphan Drug Designation, etc.)
-
Expedited Programs for Biologics (Fast Track, Priority Review, RMAT, Breakthrough Designation)
-
Regulatory Due Diligence for Biologic M&A & Licensing
U.S. FDA & Global Regulatory Submissions for Biologics
-
Investigational New Drug (IND) Applications for Biologics
-
Biologics License Applications (BLA) & Supplements
-
FDA RMAT (Regenerative Medicine Advanced Therapy) Designation
-
Orphan Drug Designation (ODD) for Biologic Therapies
-
505(b)(2) Regulatory Pathways for Biologic Reformulations & Follow-ons
EMA, MHRA, & Global Regulatory Approvals
-
EMA Marketing Authorization Applications (MAA) for Biologics
-
EU Centralized Procedure for Biologics Approval
-
MHRA Biologics Approvals & UK Market Entry Strategy
-
Global Regulatory Submissions (PMDA, NMPA, Health Canada, TGA, ANVISA, etc.)
Clinical Trial Regulatory Compliance for Biologics
-
Clinical Trial Applications (CTA) for Biologics & ATMPs
-
Good Clinical Practice (GCP) Compliance (ICH E6, FDA 21 CFR Part 312)
-
Cell & Gene Therapy-Specific Clinical Trial Regulatory Support
-
Pediatric Study Plans & Rare Disease Compliance (PREA, EU-PIP)
CMC (Chemistry, Manufacturing & Controls) Regulatory Support for Biologics
-
CMC Section Preparation for IND, BLA, and Post-Approval Changes
-
Biologic Drug Substance & Drug Product Characterization Compliance
-
ICH Q5A/B Compliance for Stability & Viral Safety Studies
-
Regulatory Oversight for Tech Transfers & Scale-Up Approvals
-
Advanced Manufacturing Technologies for Biologics (e.g., Continuous Manufacturing, Single-Use Systems)
Regulatory Labeling & Advertising Compliance
-
FDA & EMA Biologics Labeling Compliance (21 CFR 610, PLR, EU SmPC)
-
Advertising & Promotion Review for Biologics (FDA OPDP, EMA, FTC, PhRMA Code)
-
DSCSA & EU Falsified Medicines Directive (FMD) Compliance for Biologic Serialization
Post-Market Regulatory Compliance & Lifecycle Management
-
Periodic Safety Update Reports (PSURs) & Risk Management Plans (RMPs) for Biologics
-
Biologics Pharmacovigilance Compliance (FDA, EMA, ICH E2E)
-
Annual Reports, CMC Supplements, & Lifecycle Regulatory Maintenance for Biologics
-
Field Action, Recalls, & Safety Communications with Health Authorities
Regulatory Compliance for Advanced Therapies & Biosimilars
-
Cell & Gene Therapy Regulatory Pathways (FDA RMAT, EU ATMP, Japan PMDA, China NMPA, etc.)
-
Biosimilars Regulatory Approvals (FDA 351(k), EMA Biosimilar Pathway, WHO Guidelines)
-
Companion Diagnostics (CDx) & Precision Medicine Regulatory Strategy
-
Personalized Medicine & Advanced Therapeutic Compliance